

## **Minutes of the Institute Biosafety Committee Meeting**

**August 13, 2025**

**Convened at: 1:01 pm and Adjourned at 1:34 pm**

**Present:** Drs. Gelman (Chair), Ding, Gerber, Ionov, Foster, McGray, Thanavala, Mr. Hartley, Ms. Holtz, Mr. Korytko

**Absent:** Mr. Atwal, Ms. Keough, Ms. Bennett

**ORSP Staff:** Ms Oliver, Ms. Pusateri, and Ms Herter

**Guests:** None.

**Meeting Place:** Virtual meeting/Teams.

**Minutes** of July 9, 2025 were approved.

**Vote:** Unanimous.

### **Adverse Event/Accident/Incident Report**

July Employee Health Service report; no follow up required.

ORSP - No reports.

### **Old Business**

1. Safety Story; this months story highlighted the correct use of safety equipment.
2. Laboratory inspections; April, May and June are pending:
  - Laboratories were visited April 10th with Dr Ionov joining the team.
  - a. Ohm level 2+ lab: OES will follow up (see check list for details).
  - Laboratories were visited May 15th with Dr. McGray joining the team.
  - a. Chandra level 2 lab: OES will follow up (see check list for details).
  - b. Sung level 2+ lab: OES will follow up (see check list for details).
  - Laboratories were visited June 18<sup>th</sup> with Dr. Ionov joining the team.
  - a. Flow Cytometry Shared resource; OES will follow up (see checklist for details).
  - b. Hernandez level 2 lab: OES will follow up (see checklist for details).

### **New Business:**

1. 3 Laboratories were visited August 7th with Dr. Thanavala joining the team.
  - a. Liu level 2+ lab: OES will follow up (see check list for details).
  - b. McLean level 2+ lab: No follow up required.
  - c. Li, F level 2+ lab: OES will follow up (see checklist for details).The next inspection date will be Thursday September 4th with Dr. McGray joining the team.
2. Key database update: Change has been requested: The lab location currently listed for every personnel will be changed to reflect if they are personnel only on a biosafety application, or just administrative or if also listed on the IACUC application (this way required training can be accurate). This change is scheduled to be in the next maintenance update which should be at the end of August.

### **Protocol review:**

13 Biosafety applications were reviewed. 6 were continuing reviews.

### **2 Protocols referenced Virus**

Application for Lab based 1461M: Approved pending.

Reviewed by Dr. McGray

The renewal application for Lab based/Benchwork/1461M, 25-07-1681 entitled: "Genetic Targeting of T Lymphocytes to Cancer Antigens for Use in Adoptive Cell Therapy" PI: Brentjens, Renier was approved pending designated member review of a revised application.

The purpose of this protocol is to produce and test various CAR-T and armored CAR-T targeting a set of cancer-associated markers for several cancer models.  
Biosafety agents include: retrovirus, azacytidine, venetoclax, decitabine, prednisone, cetuximab, AP1903/Rimiducid.

Application for Lab based/1346M protocol: Approved.

Reviewed by Dr. Ionov

The renewal application for Lab based/bench/1346M protocol 25-07-1682 entitled: "Development of Adoptive T Cell Therapies for Human Ovarian Cancer in a SCID Mouse Model." PI: McGray, AJ Robert was approved.

The purpose of this protocol is to develop and test single or dual T cell therapies (CAR and BiTES) in ovarian cancer models.

Biosafety agents used include: retrovirus

Note: Quorum was maintained during review/approval.

Exempt from full committee review: None.

#### **Amendments:**

Application for Lab/1515M: Approved.

Reviewed by Dr. Thanavala

The amendment for 1515M protocol 24-04-1586 entitled: "Dr. Takabe Lab based Biosafety Application" PI: Takabe, Kazuaki was approved 7/22/2025.

Biosafety agents used include: 2 compounds; Propranolol and Salbutamol.

Application for protocol Lab/1612M: Approved.

Reviewed by Dr. Thanavala

The amendment for 1612M protocol 25-02-1652 entitled: "Ohm Lab Biosafety Protocol" PI: Ohm, Joyce was approved 7/22/2025.

Biosafety agents used include: F420 +/- modifications.

Application for protocol Lab/794M: Approved.

Reviewed by Dr. Gelman

The amendment for 794M protocol 24-03-1572 entitled: "Enhancement of PDT Using Biological Response Modifiers" PI: Shafirstein, Gal was approved 7/30/2025.

Biosafety agents used include: Cell lines; KPCY6419 and KPCY6419 CBC-GFP.

See attached for complete list.

Respectfully Submitted,



Irwin Gelman, PhD  
Institute Biosafety Committee Chair  
Director of Research Integration; Professor of  
Oncology